Journal article
Real-World Safety and Effectiveness of a Bevacizumab Biosimilar (ABP 215) in Metastatic Colorectal Cancer Patients in Canada
Abstract
BACKGROUND: ABP 215 is a biosimilar to the reference product, bevacizumab, and was one of the first biosimilars approved by Health Canada for the first-line treatment of metastatic colorectal cancer (mCRC). This study aimed to address gaps in real-world evidence (RWE) including patient characteristics, treatment safety (primary objective), and effectiveness (secondary objective) for first-line ABP 215 therapy in Canadian patients with mCRC.
Authors
Cheung WY; Samimi S; Ma K; Knight GJ; Kassam S; Colwell B; Beaudoin A; Vincent MD; Trinkaus M; Filion A
Journal
Clinical Colorectal Cancer, Vol. 23, No. 1, pp. 46–57.e4
Publisher
Elsevier
Publication Date
March 2024
DOI
10.1016/j.clcc.2023.10.007
ISSN
1533-0028